Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes
Authors
Keywords
Chronic Kidney Disease, Liraglutide, Exenatide, Sitagliptin, Vildagliptin
Journal
CLINICAL PHARMACOKINETICS
Volume 54, Issue 1, Pages 1-21
Publisher
Springer Nature
Online
2014-10-21
DOI
10.1007/s40262-014-0198-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Observational Study of Kidney Function and Albuminuria in Patients With Type 2 Diabetes Treated With Exenatide BID Versus Insulin Glargine
- (2014) Manjiri Pawaskar et al. ANNALS OF PHARMACOTHERAPY
- Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity?
- (2014) JM Lestner et al. BRITISH JOURNAL OF HOSPITAL MEDICINE
- A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes
- (2014) L. J. Schmidt et al. DIABETES OBESITY & METABOLISM
- Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444)
- (2014) J.H. Shon et al. DIABETES OBESITY & METABOLISM
- Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment
- (2014) P.-H. Groop et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment
- (2014) T. M. E. Davis DIABETES OBESITY & METABOLISM
- Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus
- (2014) Paul L. McCormack DRUGS
- Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus
- (2014) Gillian M. Keating DRUGS
- Albiglutide: First Global Approval
- (2014) Raewyn M. Poole et al. DRUGS
- Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
- (2014) Greg L. Plosker DRUGS
- Effects of Alogliptin in Chronic Kidney Disease Patients with Type 2 Diabetes
- (2014) Yukinao Sakai et al. INTERNAL MEDICINE
- Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease
- (2014) Thomas Idorn et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The potential for renoprotection with incretin-based drugs
- (2014) Tetsuhiro Tanaka et al. KIDNEY INTERNATIONAL
- Which incretin-based therapy for type 2 diabetes?
- (2014) André J Scheen LANCET
- Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation
- (2014) T. A. Strom Halden et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effect of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Albiglutide
- (2014) Malcolm A. Young et al. POSTGRADUATE MEDICINE
- Effects of GLP-1 in the Kidney
- (2014) Jeppe Skov REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation
- (2014) Brian P. Boerner et al. International Journal of Endocrinology
- Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels
- (2014) Yoshihide Fujigaki MEDICAL SCIENCE MONITOR
- MEDICATIONS IN THE KIDNEY
- (2014) A.J. Scheen ACTA CLINICA BELGICA
- Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Combination with Metformin
- (2013) Andrea D. Fass et al. ADVANCES IN THERAPY
- Sitagliptin—Another Option for Managing Type 2 Diabetes in Dialysis Patients?
- (2013) Wendy L. St. Peter et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial
- (2013) Juan C. Arjona Ferreira et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Acute Interstitial Nephritis After Treatment With Liraglutide
- (2013) Karim Gariani et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Renal Impairment Has No Clinically Relevant Effect on the Long-Term Exposure of Linagliptin in Patients With Type 2 Diabetes
- (2013) Christian Friedrich et al. AMERICAN JOURNAL OF THERAPEUTICS
- Efficacy and Safety of Vildagliptin in New-Onset Diabetes After Kidney Transplantation-A Randomized, Double-Blind, Placebo-Controlled Trial
- (2013) M. Haidinger et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry
- (2013) Sung-Ho Kim et al. ARCHIVES OF PHARMACAL RESEARCH
- Physiology and pathophysiology of incretins in the kidney
- (2013) Karoline von Websky et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes
- (2013) A.J. Scheen et al. DIABETES & METABOLISM
- Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus
- (2013) D.R. Owens et al. DIABETES & METABOLISM
- Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
- (2013) P.-H. Groop et al. DIABETES CARE
- Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists
- (2013) D. Dubois-Laforgue et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Clinical Practice Considerations and Review of the Literature for the Use of DPP-4 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease
- (2013) German Ramirez et al. Endocrine Practice
- Time of effect duration and administration interval for sitagliptin in patients with kidney failure
- (2013) Frieder Keller et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
- (2013) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Efficacy and safety of Jentadueto® (linagliptin plus metformin)
- (2013) André J Scheen Expert Opinion On Drug Safety
- The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis
- (2013) Yuki Fujii et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
- (2013) Thomas Forst et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment
- (2013) Yan-Ling He et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
- (2013) Hiroki Fujita et al. KIDNEY INTERNATIONAL
- Long-Term Effects of Alogliptin Benzoate in Hemodialysis Patients with Diabetes: A 2-year Study
- (2013) Yuya Nakamura et al. NEPHRON CLINICAL PRACTICE
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Glucagon-Like Peptide-1 Receptor Agonist, Liraglutide, Attenuates the Progression of Overt Diabetic Nephropathy in Type 2 Diabetic Patients
- (2013) Shigeki Imamura et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Vildagliptin and Pioglitazone in Patients With Impaired Glucose Tolerance After Kidney Transplantation
- (2013) Johannes Werzowa et al. TRANSPLANTATION
- Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis
- (2013) Hiroyuki Ito et al. Diabetes Therapy
- Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors
- (2013) Baptist Gallwitz Therapeutic Advances in Endocrinology and Metabolism
- Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment
- (2013) David Scott Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
- (2012) AMERICAN JOURNAL OF KIDNEY DISEASES
- Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
- (2012) Yan-Ling He CLINICAL PHARMACOKINETICS
- Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
- (2012) Larry K. Golightly et al. CLINICAL PHARMACOKINETICS
- Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes
- (2012) B. Detournay et al. DIABETES & METABOLISM
- Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
- (2012) J. C. Arjona Ferreira et al. DIABETES CARE
- Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study
- (2012) J. B. McGill et al. DIABETES CARE
- One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment
- (2012) W. Kothny et al. DIABETES OBESITY & METABOLISM
- Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis
- (2012) M. Pendergrass et al. DIABETES OBESITY & METABOLISM
- Acute tubulointerstitial nephritis following treatment with exenatide
- (2012) H. Nandakoban et al. DIABETIC MEDICINE
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETOLOGIA
- Exenatide Extended-Release
- (2012) Lesley J. Scott DRUGS
- Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment
- (2012) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Saxagliptin overview: special focus on safety and adverse effects
- (2012) Shamsa Ali et al. Expert Opinion On Drug Safety
- A Pharmacometric Approach to Quantify the Impact of Chronic Kidney Disease and Hemodialysis on Systemic Drug Exposure: Application to Saxagliptin
- (2012) Liping Zhang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Liraglutide-Induced Acute Kidney Injury
- (2012) Yaman Kaakeh et al. PHARMACOTHERAPY
- Use of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
- (2012) Nasser Mikhail POSTGRADUATE MEDICINE
- Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
- (2011) David W. Boulton et al. CLINICAL PHARMACOKINETICS
- Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice
- (2011) Masanori Abe et al. CURRENT DRUG METABOLISM
- Limitations and Future Treatment Options in Type 2 Diabetes With Renal Impairment
- (2011) E. Ritz DIABETES CARE
- Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
- (2011) K. J. Lipska et al. DIABETES CARE
- Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*
- (2011) U. Graefe-Mody et al. DIABETES OBESITY & METABOLISM
- Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
- (2011) M. Nowicki et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial
- (2011) V. Lukashevich et al. DIABETES OBESITY & METABOLISM
- Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
- (2011) B. Ahrén et al. DIABETES OBESITY & METABOLISM
- Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus
- (2011) Baptist Gallwitz DRUGS
- Liraglutide
- (2011) Caroline M. Perry DRUGS
- The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis
- (2011) Midori Ito et al. ENDOCRINE JOURNAL
- Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)
- (2011) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Metformin + saxagliptin for type 2 diabetes
- (2011) André J Scheen EXPERT OPINION ON PHARMACOTHERAPY
- A review of gliptins in 2011
- (2011) André J Scheen EXPERT OPINION ON PHARMACOTHERAPY
- Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study
- (2011) M. Nowicki et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Evaluation of Modification of Diet in Renal Disease study and Cockcroft-Gault equations for sitagliptin dosing
- (2011) M. Shawn McFarland et al. JOURNAL OF NEPHROLOGY
- Type 2 Diabetes Mellitus and Renal Impairment in a Large Outpatient Electronic Medical Records Database: Rates of Diagnosis and Antihyperglycemic Medication Dose Adjustment
- (2011) Juliana L. Meyers et al. POSTGRADUATE MEDICINE
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
- (2010) A. J. Scheen DIABETES OBESITY & METABOLISM
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study
- (2010) M.A. Banerji et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Exenatide and renal failure
- (2010) J. C. Ferrer-Garcia et al. DIABETIC MEDICINE
- Alogliptin
- (2010) Lesley J. Scott DRUGS
- Mild Renal Impairment and the Efficacy and Safety of Liraglutide
- (2010) Jaime Davidson et al. Endocrine Practice
- Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin
- (2010) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Addition of incretin therapy to metformin in type 2 diabetes
- (2010) André J Scheen et al. LANCET
- Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers
- (2010) Alfonso López-Ruiz et al. PHARMACY WORLD & SCIENCE
- Selection and Dosing of Medications for Management of Diabetes in Patients with Advanced Kidney Disease
- (2010) James B. Reilly et al. SEMINARS IN DIALYSIS
- Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
- (2009) Lisbeth V. Jacobsen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers
- (2009) Kyoung Soo Lim et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Exenatide-Associated Ischemic Renal Failure
- (2009) W. J. Weise et al. DIABETES CARE
- Management of Diabetes in Patients with Chronic Kidney Disease
- (2009) Ziauddin Ahmed et al. POSTGRADUATE MEDICINE
- Exenatide may aggravate moderate diabetic renal impairment: a case report
- (2008) Odd Erik Johansen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose—block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study
- (2008) Kyoung Soo Lim et al. CLINICAL THERAPEUTICS
- Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
- (2008) J. C. N. Chan et al. DIABETES OBESITY & METABOLISM
- Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
- (2008) Luc F Van Gaal et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?
- (2008) M. Haneda et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started